Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.55 |
| ▸ | ELANE | P08246 | 10/20 | 0.54 |
| ▸ | PRTN3 | P24158 | 7/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7110646 | 0.89 | ELANE (0.55) | KCNA5ELANEPRTN3 | |
| SCHEMBL7110489 | 0.87 | ELANE (0.53) | ELANEPRTN3 | |
| Sivelestat SCHEMBL28751433 | 0.86 | ELANE (0.71) | KCNA5ELANEPRTN3 | |
| Sivelestat SCHEMBL123221 | 0.86 | ELANE (0.71) | KCNA5ELANEPRTN3 | |
| Sivelestat SCHEMBL4411781 | 0.86 | ELANE (0.71) | KCNA5ELANEPRTN3 | |
| Sivelestat SCHEMBL6690886 | 0.85 | ELANE (0.69) | KCNA5ELANEPRTN3 | |
| Sivelestat SCHEMBL566914 | 0.85 | ELANE (0.69) | KCNA5ELANEPRTN3 | |
| Sivelestat SCHEMBL30864380 | 0.85 | ELANE (0.69) | KCNA5ELANEPRTN3 | |
| SCHEMBL9267298 | 0.84 | ELANE (0.56) | ELANEPRTN3 | |
| Sivelestat SCHEMBL1499929 | 0.84 | ELANE (0.68) | KCNA5ELANEPRTN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092767-A1 | Combination therapy for the treatment of inflammatory and respiratory diseases | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | claimed |
| US-20020198138-A1 | Combination therapy for the treatment of inflammatory and respiratory diseases | ELI LILLY AND COMPANY | 2002-12-26 | — | — | US | claimed |
| EP-1259260-A1 | COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES | ELI LILLY AND COMPANY (US) | 2002-11-27 | — | — | EP | claimed |
| EP-1251868-A1 | COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES | Eli Lilly & Company (US) | 2002-10-30 | — | — | EP | claimed |
| WO-2001049323-A1 | COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES | ELI LILLY AND COMPANY (US) | 2001-07-12 | — | — | WO | claimed |
| WO-2001049315-A1 | COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES | ELI LILLY AND COMPANY (US) | 2001-07-12 | — | — | WO | claimed |
| US-5403850-A | Elastase inhibitors, respiratory system disorders | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-04-04 | — | — | US | claimed |
| EP-0347168-B1 | DERIVATIVES OF P-SUBSTITUTED PHENYL ESTER OF PIVALIC ACID | ONO PHARMACEUTICAL CO (JP) | 1993-09-01 | — | — | EP | claimed |
| EP-0347168-A1 | Derivatives of p-substituted phenyl ester of pivalic acid | ONO PHARMACEUTICAL CO., LTD. (JP) | 1989-12-20 | — | — | EP | claimed |
| US-20030092767-A1 | Combination therapy for the treatment of inflammatory and respiratory diseases | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | disclosed |
| US-20020198138-A1 | Combination therapy for the treatment of inflammatory and respiratory diseases | ELI LILLY AND COMPANY | 2002-12-26 | — | — | US | disclosed |
| EP-1259260-A1 | COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES | ELI LILLY AND COMPANY (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1251868-A1 | COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES | Eli Lilly & Company (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001049323-A1 | COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES | ELI LILLY AND COMPANY (US) | 2001-07-12 | — | — | WO | disclosed |
| WO-2001049315-A1 | COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES | ELI LILLY AND COMPANY (US) | 2001-07-12 | — | — | WO | disclosed |
| US-5403850-A | Elastase inhibitors, respiratory system disorders | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-04-04 | — | — | US | disclosed |
| US-5336681-A | Elastase inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-08-09 | — | — | US | disclosed |
| US-5017610-A | Elastase inhibitor | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198138-A1 | Combination therapy for the treatment of inflammatory and respiratory diseases | SERPINB1, ELANE, MPO | KCNA5 4800/4885ELANE 2/4885PRTN3 9/4885 |
| US-20030092767-A1 | Combination therapy for the treatment of inflammatory and respiratory diseases | SERPINB1, ELANE, SPINT2 | KCNA5 4513/4885ELANE 2/4885PRTN3 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.